arrow
A

Akinori Okano

rapt therapeutics
H指数:16
被引数:1,289

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discovery and Characterization of Zelnecirnon (RPT193); a Potent and Selective CCR4 Antagonist for Allergic Disorders
2026-01-230
PRE
Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth

基于Cereblon的SOS1双功能降解剂BTX-6654靶向多个KRAS突变并抑制肿瘤生长

2024-01-152
PRE
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy
2022-09-206
PRE
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo
2020-10-0223
OAAI
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity
2020-04-1750
PREAI
Discovery of potent and selective inhibitors of USP7 with anti-tumor activity in vitro and in vivo
2019-07-011
PRE
Discovery and optimization of potent and selective inhibitors of USP7 to enhance anti-tumor immunity and target tumor growth
2018-07-010
PRE
Total Syntheses and Initial Evaluation of [Ψ[C(=S)NH]Tpg4]vancomycin, [Ψ[C(=NH)NH]Tpg4]vancomycin, [Ψ[CH2NH]Tpg4]vancomycin, and Their (4-Chlorobiphenyl)methyl Derivatives: Synergistic Binding Pocket and Peripheral Modifications for the Glycopeptide Antibiotics

[Ψ[C(= S)NH]Tpg4] 万古霉素、 [Ψ[C(= NH)NH]Tpg4] 万古霉素、 [Ψ[CH2NH]Tpg4] 万古霉素及其 (4-氯联苯) 甲基衍生物的总合成和初步评价: 糖肽抗生素的协同结合口袋和外周修饰

2015-03-0967
OAAI